Association between monocyte count and risk of incident CKD and progression to ESRD

Clinical Journal of the American Society of Nephrology

Volumn 12, Issue 4, 2017, Pages 603-613

  Bowe, Benjamin ^a   Xie, Yan ^a   Xian, Hong ^a,c   Li, Tingting ^a,b   Al Aly, Ziyad ^a,b,d  

^a Research and Medical Service   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemokine; Chemokine receptor; Chronic; Chronic kidney disease; Clinical epidemiology; Creatinine; Disease Progression; EGFR decline; EGFR slope; End stage kidney disease; Epidemiologic Studies; Epidemiology and outcomes; ESRD; Follow Up Studies; Kidney; Kidney Failure; Kidney transplantation; Monocytes; Renal dialysis; Renal function decline; Renal Insufficiency; Renal progression; United States; Veterans; White blood cell

Indexed keywords

ADULT; AGED; ARTICLE; ATTRIBUTABLE RISK; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DISEASE COURSE; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MONOCYTE; OBSERVATIONAL STUDY; RISK FACTOR; SENSITIVITY ANALYSIS; BLOOD; DISEASE EXACERBATION; GLOMERULUS FILTRATION RATE; INCIDENCE; KAPLAN MEIER METHOD; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; UNITED STATES;

CREATININE;

AGED; CREATININE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MONOCYTES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; UNITED STATES;

EID: 85020260684     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09710916     Document Type: Article

References (42)

1. Ghattas A, Griffiths HR, Devitt A, Lip GY, Shantsila E: Monocytes in coronary artery disease and atherosclerosis: Where are we now? J Am Coll Cardiol 62: 1541–1551, 2013
2. Swaminathan S, Shah SV: Novel inflammatory mechanisms of accelerated atherosclerosis in kidney disease. Kidney Int 80: 453– 463, 2011
3. Adamsson Eryd S, Smith JG, Melander O, Hedblad B, EngströmG: Incidence of coronary events and case fatality rate in relation to blood lymphocyte and neutrophil counts. Arterioscler Thromb Vasc Biol 32: 533–539, 2012
4. Johnsen SH, Fosse E, Joakimsen O, Mathiesen EB, Stensland-Bugge E, Njølstad I, Arnesen E: Monocyte count is a predictor of novel plaque formation: A 7-year follow-up study of 2610 persons without carotid plaque at baseline the Tromsø Study. Stroke 36: 715–719, 2005
5. Nasir K, Guallar E, Navas-Acien A, Criqui MH, Lima JA: Relationship of monocyte count and peripheral arterial disease: Results from the National Health and Nutrition Examination Survey 1999-2002. Arterioscler Thromb Vasc Biol 25: 1966–1971, 2005
6. Cortina MG, Campello AR, Conde JJ, Ois A, Voustianiouk A, Téllez MJ, Cuadrado E, Roquer J: Monocyte count is an underlying marker of lacunar subtype of hypertensive small vessel disease. Eur J Neurol 15: 671–676, 2008
7. Ganda A, Magnusson M, Yvan-Charvet L, Hedblad B, Engström G, Ai D, Wang TJ, Gerszten RE, Melander O, Tall AR: Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis. Circulation 127: 988–996, 2013
8. Evangelopoulos AA, Vallianou NG, Bountziouka V, Katsagoni C, Bathrellou E, Vogiatzakis ED, Bonou MS, Barbetseas J, Avgerinos PC, Panagiotakos DB: Association between serum cystatin C, monocytes and other inflammatory markers. Intern Med J 42: 517–522, 2012
9. Ricardo SD, van Goor H, Eddy AA: Macrophage diversity in renal injury and repair. J Clin Invest 118: 3522–3530, 2008
10. Lech M, Gröbmayr R, Ryu M, Lorenz G, Hartter I, Mulay SR, Susanti HE, Kobayashi KS, Flavell RA, Anders HJ: Macrophage phenotype controls long-term AKI outcomes–kidney regeneration versus atrophy. J Am Soc Nephrol 25: 292–304, 2014
11. Anders HJ, Ninichuk V, Schlöndorff D: Progression of kidney disease: Blocking leukocyte recruitment with chemokine receptor CCR1 antagonists. Kidney Int 69: 29–32, 2006
12. Chung AC, Lan HY: Chemokines in renal injury. J Am Soc Nephrol 22: 802–809, 2011
13. Zimmermann HW, Seidler S, Nattermann J, Gassler N, Hellerbrand C, Zernecke A, Tischendorf JJ, Luedde T, Weiskirchen R, Trautwein C, Tacke F: Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One 5: e11049, 2010
14. Ju C, Tacke F: Hepatic macrophages in homeostasis and liver diseases: From pathogenesis to novel therapeutic strategies. Cell Mol Immunol 13: 316–327, 2016
15. Xie Y, Bowe B, Xian H, Balasubramanian S, Al-Aly Z: Renal function trajectories in patients with prior improved eGFR slopes and risk of death. PLoS One 11: e0149283, 2016
16. Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z: Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol 27: 3153–3163, 2016
17. Bowe B, Xie Y, Xian H, Balasubramanian S, Al-Aly Z: Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. Kidney Int 89: 886–896, 2016
18. Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS; CKD Prognosis Consortium: Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311: 2518–2531, 2014
19. Al-Aly Z: Prediction of renal end points in chronic kidney disease. Kidney Int 83: 189–191, 2013
20. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA: Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43: 1130–1139, 2005
21. Bowe B, Xie Y, Xian H, Balasubramanian S, A Zayed M, Al-Aly Z: High density lipoprotein cholesterol and the risk of all-cause mortality among U.S. veterans [published online ahead of print August 11, 2016]. ClinJ AmSocNephrol doi:10.2215/CJN.00730116
22. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612, 2009
23. Kleinbaum DG, Klein M: Survival Analysis: A Self-Learning Text, New York, Springer, 2005
24. Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z: Long term kidney outcomes among proton pump inhibitors users without intervening acute kidney injury. Kidney Int, 2016, in press
25. Laaksonen MA, Virtala E, Knekt P, Oja H, Härkänen T: SAS Macros for calculation of population attributable fraction in a cohort study design. J Stat Softw 43: 1–25, 2011
26. Anonymous: Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int Suppl (2011) 3: 63–72, 2013
27. Al-Aly Z, Balasubramanian S, McDonald JR, Scherrer JF, O’Hare AM: Greater variability in kidney function is associated with an increased risk of death. Kidney Int 82: 1208–1214, 2012
28. Al-Aly Z, Zeringue A, Fu J, Rauchman MI, McDonald JR, El-Achkar TM, Balasubramanian S, Nurutdinova D, Xian H, Stroupe K, Abbott KC, Eisen S: Rate of kidney function decline associates with mortality. J Am Soc Nephrol 21: 1961–1969, 2010
29. Bowe BXY, Xian H, Lian M, Al-Aly Z: Geographic variation and US county characteristics associated with rapid kidney function decline. Kidney Int Rep 2: 5–17, 2017
30. Reddan DN, Klassen PS, Szczech LA, Coladonato JA, O’Shea S, Owen WF Jr., Lowrie EG: White blood cells as a novel mortality predictor in haemodialysis patients. Nephrol Dial Transplant 18: 1167–1173, 2003
31. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy Z: Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 3: 505–521, 2008
32. Anders HJ, Belemezova E, Eis V, Segerer S, Vielhauer V, Perez de Lema G, Kretzler M, Cohen CD, Frink M, Horuk R, Hudkins KL, Alpers CE, Mampaso F, Schlöndorff D: Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J Am Soc Nephrol 15: 1504–1513, 2004
33. Anders HJ, Vielhauer V, Frink M, Linde Y, Cohen CD, Blattner SM, Kretzler M, Strutz F, Mack M, Gröne HJ, Onuffer J, Horuk R, Nelson PJ, Schlöndorff D: A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest 109: 251–259, 2002
34. Lee JW, Cho E, Kim MG, Jo SK, Cho WY, Kim HK: Proinflammatory CD14(+)CD16(+) monocytes are associated with vascular stiffness in predialysis patients with chronic kidney disease. Kidney Res Clin Pract 32: 147–152, 2013
35. Gao W, Topham PS, King JA, Smiley ST, Csizmadia V, Lu B, Gerard CJ, Hancock WW: Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest 105: 35–44, 2000
36. Ninichuk V, Gross O, Reichel C, Khandoga A, Pawar RD, Ciubar R, Segerer S, Belemezova E, Radomska E, Luckow B, Perez de Lema G, Murphy PM, Gao JL, Henger A, Kretzler M, Horuk R, Weber M, Krombach F, Schlöndorff D, Anders HJ: Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease. J Am Soc Nephrol 16: 977–985, 2005
37. Rodgers KD, Rao V, Meehan DT, Fager N, Gotwals P, Ryan ST, Koteliansky V, Nemori R, Cosgrove D: Monocytes may promote myofibroblast accumulation and apoptosis in Alport renal fibrosis. Kidney Int 63: 1338–1355, 2003
38. Awad AS, Kinsey GR, Khutsishvili K, Gao T, Bolton WK, Okusa MD: Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. Am J Physiol Renal Physiol 301: F1358– F1366, 2011
39. Al-Aly Z: Phosphate, oxidative stress, and nuclear factor-kB activation in vascular calcification. Kidney Int 79: 1044–1047, 2011
40. Marincola FM: In support of descriptive studies; relevance to translational research. J Transl Med 5: 21, 2007
41. Xie Y, Bowe B, Xian H, Balasubramanian S, Al-Aly Z: Rate of kidney function decline and risk of hospitalizations in stage 3A CKD. Clin J Am Soc Nephrol 10: 1946–1955, 2015
42. Xie Y, Bowe B, Xian H, Balasubramanian S, Al-Aly Z: Estimated GFR trajectories of people entering CKD stage 4 and subsequent kidney disease outcomes and mortality. Am J Kidney Dis 68: 219–228, 2016